Product research for clinical development in the field of psychiatric diseases and the accompanying cognitive deficit therapies of such illnesses.
START DATE: 2008-10-01


 Exploratory, preclinical and translational research of candidate drugs with an innovative mode of action (GABAergic or serotoninergic ligands and modulators of neuroplasticity), and development of candidate drugs effective for psychiatric diseases—particularly those that involve anxiety, depression or schizophrenia and/or the associated cognitive deficiency.
Exploring the complex and detailed mechanism of action of the candidate drug molecules to be developed using proteomic studies performed from specific mouse brain areas after subchronic treatment.


In cooperation with the University of Szeged, we have established a research platform that aims to develop new drug candidates with an innovative mode of action—to be used in psychiatric diseases and associated cognitive deficiencies. Our research chemists have produced 744 new patentable molecules using novel molecule modelling techniques, amongst others.
In the substance screening campaign, we successfully revealed the individual mechanism of action of selective targets compounds—using molecular biology techniques. With the help of proteomic studies, which are considered a novelty in the Hungarian industry research environment, we identified a number of new target proteins and formulated new working hypotheses. We have demonstrated the efficacy of our compounds in newly designed behavioral tests—for anxiety diseases, depression, schizophrenia, Alzheimer’s disease, and cognitive impairment associated with these conditions.
The project resulted in a molecule portfolio of six compounds—which were proven to be suitable for clinical development, based on the performed tests.
The scientific and original drug research cooperation between the members of the consortium proved to be very useful, and the professional knowledge and research infrastructure of the different partners complemented themselves well. While the strength of the researchers at the pharmaceutical company presented itself in chemical synthesis processes and in some pharmacological tests,  the academic partner provided the missing experimental capabilities and competences for the industrial consortium leader.


Information on the proposed project:: 

Principal of the tender: National Research And Technology Office
Title and code of the call for tender proposals: “National Technology Program”, TECH_08
Title and ID of proposed project: “Researching drug candidates suitable for clinical development in the therapeutic area of psychiatric diseases and the associated cognitive deficit”, TECH_08-A1-2008-0305
Submission date of proposal: 27/03/2008
Date of decision about funding: 15/07/2008
Total granted amount: HUF 800,000,000, from which:
          ● Egis Pharmaceuticals PLC: HUF 600,000,000
          ● University of Szeged (consortium partner): HUF 200,000,000
Time period for project implementation: 01/10/2008 - 30/09/2012
Total costs of the project: HUF 1,400,000,000
Provided funding: HUF 800,000,000

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox